News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

PledPharma Capital Markets Day, March 26

March 14, 2019

Stockholm, March 14, 2019. PledPharma, an innovative, unique and integrated pharmaceutical drug development company,  focusing on improving treatments for diseases with substantial unmet medical need, has the pleasure of inviting investors, financial analysts and media to PledPharma’s Capital Markets Day (CMD) on 26th March 2019.

An overview of the program as follows;

  1. Introduction
  2. Company overview and drug candidates in development
  3. PledOx® in Chemotherapy Induced Peripheral Neuropathy (CIPN)
    1. Unmet medical need
    2. Development of PledOx® in CIPN with oxaliplatin
    3. Indication expansion – CIPN with taxanes
  4. Lunch
  5. Aladote® in Paracetamol Overdose (POD)
    1. Unmet medical need
    2. Aladote® proof of principle study results
    3. Development of Aladote® to prevent acute liver injury caused by POD
    4. Commercial opportunity in POD
  6. Corporate strategy
    1. Direction and opportunities to enhance value
    2. Business development
    3. Finance and up-listing to Nasdaq Stockholm Main Market
  7. Closing remarks

Time: Tuesday March 26th, at 10:00-15:00 CET

Venue: Redeye, Mäster Samuelsgatan 42, 10th floor, Stockholm

To attend – sign up here!

Presentations will be held in English.

The CMD will be broadcasted live at

Speakers at the CMD include the Chairman of the Board, Håkan Åström, the CEO, Nicklas Westerholm and members from the management team as well as two key opinion leaders, Dr. James Dear, Edinburgh University and Prof. Per Pfeiffer, Odense University. The event will be moderated by Lars Hevreng from Vator Securities. See biographies.

Biography Dr. James Dear:

Dr. Dear began his medical training at University College London and completed a PhD in Pharmacology before finishing his clinical training at Brasenose College, Oxford University. After junior medical jobs at the John Radcliffe Hospital in Oxford and a variety of London teaching hospitals, Dr Dear spent 2 years at a research fellow at the National Institutes of Health, Bethesda, USA. This time was spent learning proteomic and imaging techniques as applied to acute kidney and liver injury. Since 2005, Dr Dear has been a Clinical Lecturer then Senior Clinical Lecturer and now Clinical Reader in Clinical Pharmacology at the Royal Infirmary of Edinburgh/Edinburgh University. In 2012, Dr. Dear was awarded an NHS Research Scotland (NRS) Career Research Fellowship. In 2016 Dr. Dear won the British Pharmacological Societies Grahame-Smith Prize for Research Excellence in Clinical Pharmacology. Dr. Dear has published 126 papers (H-index 32) and has received over >UK£2 million in funding in the last 5 years. Dr. Dear is a member of the Expert Advisory Group for the EU IMI funded TransBioLine Consortium.

Biography Prof. Per Pfeiffer

Prof. Pfeiffer, MD, PhD, is currently Professor at the University of Southern Denmark, Head of Clinical Research Unit and the Digestive Oncology Unit at department of Oncology, Odense University Hospital, Denmark.

Prof. Per Pfeiffer obtained his degree of MD and PhD at the University of Southern Denmark. Per Pfeifer trained in internal medicine, surgery and oncology in Odense and Aarhus, Denmark and became consultant in Digestive Oncology at department of Oncology, Odense University Hospital in 1998.

His research interests include primarily clinical cancer research in patients with gastrointestinal cancer, primarily colorectal, gastric and pancreatic cancer.

He has a large clinical activity in Odense, Denmark and is involved and leads National and Nordic clinical and translational research projects on gastrointestinal cancer.

He has published more than 170 peer-reviewed articles (H-factor 32) in prestigious journals including Journal of Clinical Oncology, Annals of Oncology, British Journal of Cancer and European Journal of Cancer, and given more than 100 congress presentations and lectures on gastrointestinal cancer. Dr. Pfeiffer is member of the Nordic Colorectal Cancer Biomodulation Group, he is chairman of the Danish Pancreatic Cancer Group and Danish Colorectal Oncology Group. He serves as co-editor and reviewer for several oncology journals.

Short Biography Lars Hevreng

Lars Hevreng is Head of Equity Research with a healthcare focus at Vator Securities. He has a background from Roche, SEB Enskilda and Danske Bank.

For further information, please contact:

Yilmaz Mahshid, CFO
Tel. +46-(0)72 231 68 00

About PledPharma

PledPharma develops new drugs that protect the body against oxidative stress – a potentially debilitating and sometimes life-threatening condition that can be caused by chemotherapy treatment and following acetaminophen (paracetamol) overdose. The company’s most advanced project PledOx® is being developed to reduce nerve damage associated with chemotherapy. A global phase III program is ongoing. The drug candidate Aladote® is being developed to reduce the risk of acute liver failure associated with acetaminophen poisoning. A proof of principle study has been successfully completed and will serve as the basis for the continued development. PledPharma (STO: PLED) is listed on Nasdaq First North. Erik Penser Bank is the company’s Certified Adviser (tel +46 8 463 83 00, For more information, see




Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10